Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

y participants were encouraging. Genzyme expects to release

results by mid year for a larger number of patients, including results

for those patients who have completed the one year trial. Final

results for all trial participants will be available in the first

quarter of 2009. Genzyme is currently developing clinical trial

protocols for two Phase 3 studies of Genz-112638, and the company

anticipates initiating these studies early next year. Genzyme believes

that this oral product may offer a more convenient treatment option for

some patients.

Mipomersen for high-risk cardiovascular disease

Genzyme expects to finalize its license of mipomersen from Isis

Pharmaceuticals in the second quarter and subsequently communicate a

development plan for the product. Mipomersen is a lipid-lowering agent

being developed primarily for patients at significant cardiovascular

risk who are unable to achieve target cholesterol levels with statins

alone or who are intolerant of statins. The product offers an

innovative approach to addressing a serious unmet medical need, and

Genzyme believes it could prove to be the most effective lipid-lowering

agent for high risk cardiovascular disease patients for whom

conventional therapies are not sufficient. The product may provide

significant benefit over the standard of care and targets a well-defined

and severely ill patient population. Mipomersen is currently being

studied in a Phase 3 clinical trial involving patients with homozygous

familial hypercholesterolemia.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q2 2008, YE 2008 and YE 20011 earnings guidance; its anticipated CAGR through 2011; its expectations for approval of Myo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Rice University scientists who created a deicing film for ... as a transparent coating for glass. , The ... colleagues could keep glass surfaces from windshields to skyscrapers ... to radio frequencies (RF). , The technology was ... Applied Materials and Interfaces . , The ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... 2014 CIRTEC Medical Systems’ Board of ... CEO of CIRTEC. , “I am delighted to ... Company.” noted Brian Highley. “The company has made great ... organic growth over the past two years. The goal ... improve and expand the services Cirtec offers its medical ...
(Date:9/16/2014)... 16, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... completion of the Company,s Investor Day in ... irritable bowel syndrome (IBS) program, including its novel, ... In the keynote presentation, Mark Pimentel ...
Breaking Biology Technology:Nanoribbon film keeps glass ice-free 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... CHERRY HILL, N.J., Sept. 21 Nuvilex, Inc. (OTC Bulletin ... venture partner with Reme-Flu(TM), will be incorporating Syn-X9(TM) proprietary delivery ... remedy designed to help prevent and treat flu-type symptoms resulting ... , , The unique attributes ...
... Merrimack Pharmaceuticals, Inc., announced today that Clet Niyikiza, Ph.D., ... Niyikiza comes to Merrimack from GlaxoSmithKline (GSK) where he was ... Niyikiza has extensive drug development experience with a career ... which he has led ten New Drug Application teams that ...
... , , ROCKVILLE, Md., Sept. 21 ... the U.S. Food and Drug Administration (FDA) has approved its Investigational New ... Lateral Sclerosis (ALS or Lou Gehrig,s disease) with its spinal cord stem ... ) , , Neuralstem is the first ...
Cached Biology Technology:Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 2Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 3Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development 2Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 2Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 3Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 4
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
(Date:9/16/2014)... a 10-km diameter chunk of rock hit the Yukatan peninsula ... the force of 100 teratons of TNT. It left a ... wildfires, global earthquakes and volcanism are widely accepted to have ... of the mammals. But what happened to the plants on ... researchers from the University of Arizona reveals that the meteorite ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... a sudden halt, the carbon dioxide already in Earth,s atmosphere ... according to Princeton University-led research published in the journal ... take a lot less carbon than previously thought to reach ... an Earth on which, after 1,800 billion tons of carbon ...
... Think Greenland,s ice sheet is small today? It was ... history from 3-5,000 years ago, according to scientists who studied ... interpreting the Arctic fossil record. "What,s really interesting about this ... 5,000 years ago, maybe as late as 4,000 years ago. The ...
... Gregg, an assistant professor of mechanical engineering and bioengineering ... Computer Science this fall, is a recipient of a ... for research that will combine robot control theory and ... orthotic devices. "According to the American Society of ...
Cached Biology News:Even if emissions stop, carbon dioxide could warm Earth for centuries 2Even if emissions stop, carbon dioxide could warm Earth for centuries 3Greenland's shrunken ice sheet: We've been here before 2Greenland's shrunken ice sheet: We've been here before 3UT Dallas professor wins $2.3 million NIH award 2UT Dallas professor wins $2.3 million NIH award 3
Microlite 2+ Plate, round bottom; an irradiated, high binding surface with enhanced dynamic range, extra high reflectivity and minimal cross talk for low signal luminescent reactions....
... freezers offer a superior sample management ... samples with high capacities. Innovative insulation ... ensure excellent warming protection and ensure ... accessories simplify tracking of sample location ...
...
Verotoxin IIbeta (457)...
Biology Products: